Neuropilins and semaphorins - from angiogenesis to autoimmunity

Autoimmunity Reviews

Volumn 9, Issue 12, 2010, Pages 825-829

  Vadasz, Z ^a   Attias, D ^a   Kessel, A ^a   Toubi, E ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Autoimmunity; Immune system; Neuropilin; Semaphorin

Indexed keywords

NEUROPILIN; SEMAPHORIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; IMMUNE SYSTEM; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MOLECULE; MULTIPLE SCLEROSIS; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL DIFFERENTIATION; NONHUMAN; PANNUS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE PROGRESSION; HUMANS; IMMUNOPHILINS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; SEMAPHORINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956925423     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.014     Document Type: Review

References (49)

1. Folkman J., Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992, 313:355-364.
2. Tsonis I.A., Avrameas S., Moutsopoulos H.M. Autoimmunity and pathophysiology. J Autoimmun 2007, 29:203-205.
3. Kirka S.L., Karlika S.J. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003, 21:353-363.
4. Bagli E., Xagorari A., Papetropoulos A., Murphy C., Fotsis T. Angiogenesis in inflammation. Autoimmun Rev 2004, 3(Suppl1):s26.
5. Colombo B.M., Cacciapaglia F., Puntoni M., Murdaca G., Rossi E., Rodriguez G., et al. Traditional and non-traditional risk factors in accelerated atherosclerosis in SLE: role of VEGF (VEGATS study). Autoimmun Rev 2009, 8:309-315.
6. Caravalho J.F., Blank M., Shoenfeld Y. VEGF in autoimmune disease. J Clin immune 2007, 27(3):246-256.
7. Robak E., Woźniacka A., Sysa-Jedrzejowska A., Stepień H., Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw 2001, 12:445-452.
8. Ikeda M., Hosoda Y., Hirose S., Okada Y., Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000, 191:426-433.
9. Lainer D.T., Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Invest Drugs 2005, 14:1-17.
10. Kolodkin A.L., Levengood D.V., Rowe E.G., Tai Y.T., Giger R.J., Ginty D.D. Neuropilin is a semaphorin III receptor. Cell 1997, 90:753-762.
11. Staton C.A., Kumar I., Reed M.W., Brown N.J. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007, 212:237-248.
12. Klagsbrun M., Takashima S., Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002, 515:33-48.
13. Gluzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G. Neuropilin-2 and neuropilin-1 receptors for VEGF165 and PLGF-2, but only neuropilin-2 functions as a receptor for VEGF145. J Biol Chem 2002, 275:19040-19045.
14. Favier B., Alam A., Barron B., Bonnin J., Laboudie P., Fons P., et al. Neuropilin-2 interacts with VEGF-R2 and VEGF-R3 and promotes human endothelial cell survival and migration. Blood 2006, 108:1243-1250.
15. Fuh G., Garcia K.C., de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem 2000, 275:26690-26695.
16. Lepelletier Y., Smaniotto S., Hadj-Slimane R., Villa-Verde D.M.S., Nogueira A.C., Dardenne M., et al. Control of human thymocyte migration by neuropilin- 1/semaphorin 3A mediated interactions. Proc Natl Acad Sci USA 2007, 104:5545-5550.
17. Tordjman R., Lepelletier Y., Lemarchandel V., Cambot M., Gaulard P., Hermine O., et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002, 3:477-482.
18. Gorelik G., Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev 2009, 8:196-198.
19. Sarris M., Andersen K.G., Randow F., Mayr L., Betz A.G. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28:402-413.
20. Battaglia A., Buzzonetti A., Baranello C., Ferrandina G., Martinelli E., Fanfani F., et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009, 58(9):1363-1373.
21. Bourbie-Vaudaine S., Blanchard N., Hivroz C., Roméo P.H. Dendritic cells can turn CD41 T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J Immunol 2006, 177:1460-1469.
22. Gomez-Martin D., Diaz-Zamudio M., Alcocer-Varela J. Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmun Rev 2008, 7:284-290.
23. Glinka Y., Prud'homme G.J. Neuropilin-1 is a receptor for transforming growth factor-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol 2008, 84:302-310.
24. Oida T., Xu L., Weiner H.L., Kitani A., Strober W. TGF-β mediated suppression by CD4-CD25 T cells is facilitated by CTLA-4 signaling. J Immunol 2006, 177:2331-2339.
25. Sthoeger Z.M., Sharabi A., Molad Y., Asher I., Zinger H., Dayan M., et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009, 33(1):77-82.
26. Koch A.E. Angiogenesis: Implication for rheumatoid arthritis. Arthritis Rheum 1998, 41:951-962.
27. Mika I., Yasuhiro H. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000, 191:426-433.
28. Kim W.U., Yoo Kang S.S., SA Hong K.H., Bae D.G., Lee M.S., Hong S.W., et al. Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation1. J Immunol 2006, 177:5727-5735.
29. Kong J.S., Yoo S.A., Kim J.W., Yang S.P., Chae C.B., Tarallo V., et al. Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis Rheum 2010, 62(1):179-190.
30. Yazdani U., Terman J.R. The semaphorins. Genome Biol 2006, 7:211.1-211.14.
31. Semaphorin Nomenclature Committee UniWed nomenclatur for the semaphorins/collapsins. Cell 1999, 97:551-552.
32. Negishi M., Oinuma I., Katoh H. Plexins: axon guidance and signal transduction. Cell Mol Life Sci 2005, 62:1363-1371.
33. Takahashi K., Ishida M., Hirokawa K., Takahashi H. Expression of the semaphorins Sema 3D and Sema 3F in the developing parathyroid and thymus. Dev Dyn 2008, 237:1699-1708.
34. Kumanogoh A., Watanabe C., Lee I., Wang X., Shi W., Araki H., et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 2000, 13:621-631.
35. Takegahara N., Takamatsu H., Toyofuku T., Tsujimura T., Okuno T., Yukawa K., et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 2006, 8:615-622.
36. Shi W., Kumanogoh A., Watanabe C., Uchida J., Wang X., Ti Yasu, et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 2000, 13:633-642.
37. Adachi T., Wienands J., Wakabayashi C., Yakura H., Reth M., Tsubata T. SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates. J Biol Chem 2001, 276:26648-26655.
38. Ferraccioli G., Tolusso B. Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 2007, 7:109-113.
39. Youinou Pierre B cell conducts the lymphocyte orchestra. J Autoimmun 2007, 28:143-151.
40. Kumanogoh A., Shikina T., Watanabe C., Takegahara N., Suzuki K., Yamamoto M., et al. Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. Int Immunol 2005, 17:1277-1282.
41. Delaire S., Elhabazi A., Bensussan A., Boumsell L. CD100 is a leukocyte semaphorin. Cell Mol Life Sci 1998, 54:1265-1276.
42. Kumanogoh A., Shikina T., Suzuki K., Uematsu S., Yukawa K., Kashiwamura S.I., et al. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. Immunity 2005, 22:305-316.
43. Kumanogoh A., Marukawa S., Suzuki K., Takegahara N., Watanabe C., Ch'ng E., et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002, 419:629-633.
44. Kumanogoh A., Kikutani H. Semaphorins and their receptors: novel features of neural guidance molecules. Proc Jpn Acad 2010, 86(6):611-620.
45. Suzuki K., Okuno T., Yamamoto M., Pasterkamp R.J., Takegahara N., Takamatsu H., et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 2007, 446:680-684.
46. Suzuki K., Kumanogoh A., Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008, 9(1):17-23.
47. Peng S.L. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009, 8:179-183.
48. Nakano S., Morimoto S., Suzuki J., Mitsuo A., Nakiri Y., Katagiri A., et al. Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis. Autoimmunity 2007, 40(1):9-15.
49. Won Kim C., Cho E.H., Lee Y.J., Kim Y.H., et al. Disease-specific proteins from rheumatoid arthritis patients. J Korean Med Sci 2006, 21:478-484.